EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma

Katie M Campbell, Meelad Amouzgar, Shannon M Pfeiffer, Timothy R Howes, Egmidio Medina, Michael Travers, Gabriela Steiner, Jeffrey S Weber, Jedd D Wolchok, James Larkin, F Stephen Hodi, Silvia Boffo und 7 weitere

Cancer Cell · 2023

DOI: 10.1016/j.ccell.2023.03.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2023. Verfasst von Katie M Campbell und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: katie…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansCTLA-4 AntigenBiomarkers, TumorImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

immune checkpoint blockadeimmunotherapymelanomameta-analysis

Substanzen

CTLA-4 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: katiecampbell@mednet.ucla.edu.
  • Department of Pathology, Stanford University, Stanford, CA 94305, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Perlmutter Cancer Center, NYU School of Medicine, New York, NY 10016, USA.
  • Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan K…

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute
  • Cancer Research Institute
  • V Foundation for Cancer Research
  • NYU Langone Medical Center
  • Parker Institute for Cancer Immunotherapy
  • Weill Cornell Medicine

Zitieren

APA

Campbell, K. M., Amouzgar, M., Pfeiffer, S. M., Howes, T. R., Medina, E., Travers, M., Steiner, G., Weber, J. S., Wolchok, J. D., Larkin, J., Hodi, F. S., Boffo, S., Salvador, L., Tenney, D., Tang, T., Thompson, M. A., Spencer, C. N., Wells, D. K., & Ribas, A. (2023). Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell. https://doi.org/10.1016/j.ccell.2023.03.010

Vancouver

Campbell KM, Amouzgar M, Pfeiffer SM, Howes TR, Medina E, Travers M, et al. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell. 2023. doi:10.1016/j.ccell.2023.03.010

BibTeX
@article{Campbell2023,
  author = {Campbell, Katie M and Amouzgar, Meelad and Pfeiffer, Shannon M and Howes, Timothy R and Medina, Egmidio and Travers, Michael and Steiner, Gabriela and Weber, Jeffrey S and Wolchok, Jedd D and Larkin, James and Hodi, F Stephen and Boffo, Silvia and Salvador, Lisa and Tenney, Daniel and Tang, Tracy and Thompson, Marshall A and Spencer, Christine N and Wells, Daniel K and Ribas, Antoni},
  title = {Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma},
  journal = {Cancer Cell},
  year = {2023},
  doi = {10.1016/j.ccell.2023.03.010}
}
Kostenlos starten →